Clinical Trial Update: IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial updating results for IPX056 in established spasticity due to multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• IPX056

Snippet

Sponsor: Impax Laboratories, LLC | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED